Atropine
Atropen, Atropine, Duodote, Enlon, Lomotil, Motofen (atropine) is a small molecule pharmaceutical. Atropine was first approved as Atropen on 1982-01-01. It is used to treat bradycardia, heart arrest, poisoning, sinoatrial block, and stomach ulcer amongst others in the USA. The pharmaceutical is active against muscarinic acetylcholine receptor M3, muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M1, muscarinic acetylcholine receptor M5, and muscarinic acetylcholine receptor M4. In addition, it is known to target alpha-2A adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Atropine, Isopto atropine (discontinued: Atropen, Atropine)
CombinationsDiphenoxylate atropine, Duodote, Lomotil, Motofen (discontinued: Atnaa, Atropine demerol, Colonaid, Diphenoxylate atropine, Diphenoxylate w/ atropine, Enlon, Logen, Lomanate, Lomotil, Lonox, Low-quel, Meperidine atropine, Motofen)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Atropine sulfate
+
Edrophonium chloride
Atropine sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ATROPINE SULFATE | Accord Healthcare | N-214652 RX | 2020-09-29 | 2 products, RLD, RS |
| ISOPTO ATROPINE | Alcon Research | N-208151 RX | 2016-12-01 | 1 products, RLD, RS |
| ATROPINE SULFATE | Bausch Health Companies | N-213581 RX | 2022-03-15 | 1 products, RLD, RS |
| ATROPINE SULFATE | Fresenius Kabi | N-209260 RX | 2018-01-26 | 1 products, RLD, RS |
| ATROPINE SULFATE | Hospira | N-021146 RX | 2001-07-09 | 3 products, RLD, RS |
| ATROPINE SULFATE | Rising Pharmaceuticals | N-206289 RX | 2014-07-18 | 1 products, RLD |
Show 1 discontinued
Atropine sulfate
+
Diphenoxylate hydrochloride
Atropine sulfate
+
Difenoxin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MOTOFEN | Sebela Pharmaceuticals | N-017744 RX | 1982-01-01 | 1 products, RLD, RS |
Show 1 discontinued
Atropine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ATROPEN | Meridian Medical Technologies | N-017106 DISCN | 1982-01-01 | 4 products, RLD |
| ATROPINE (AUTOINJECTOR) | Rafa Laboratories | N-212319 DISCN | 2018-07-09 | 1 products |
Hide discontinued
Atropine
+
Pralidoxime chloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DUODOTE | Meridian Medical Technologies | N-021983 RX | 2006-09-28 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| atnaa | 2007-05-17 | |
| atnaa atropine and pralidoxime chloride | New Drug Application | 2022-07-18 |
| atropen auto-injector | New Drug Application | 2022-09-15 |
| atropine | ANDA | 2024-10-16 |
| atropine care | unapproved drug other | 2011-01-06 |
| atropine sulfate | ANDA | 2024-12-17 |
| cold and flu relief | unapproved drug other | 2021-01-13 |
| diphenoxylate hcl and atropine sulfate | ANDA | 2010-03-24 |
| diphenoxylate hydrochloride and atropine sulfate | ANDA | 2024-11-13 |
| direct rx | NDA authorized generic | 2015-08-05 |
Show 14 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A03: Drugs for functional gastrointestinal disorders
— A03B: Belladonna and derivatives containing drugs, plain for functional gastrointestinal disorders
— A03BA: Belladonna alkaloids, tertiary amines for functional gastrointestinal disorders
— A03BA01: Atropine
— A03C: Antispasmodics in combination with psycholeptics
— A03CB: Belladonna and derivatives in combination with psycholeptics
— A03CB03: Atropine and psycholeptics
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01F: Mydriatics and cycloplegics
— S01FA: Anticholinergic mydriatics and cycloplegics
— S01FA01: Atropine
Clinical
Clinical Trials
359 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myopia | D009216 | EFO_0003927 | H52.1 | 11 | 14 | 17 | 10 | 27 | 73 |
| Neuromuscular blockade | D019148 | — | — | — | 2 | 3 | 12 | 4 | 21 |
| Anesthesia | D000758 | — | — | — | — | 3 | 2 | 7 | 12 |
| Hypotension | D007022 | EFO_0005251 | I95 | 1 | — | — | 2 | 8 | 11 |
| Poisoning | D011041 | EFO_0008546 | T65.91 | 2 | 2 | 2 | 2 | 4 | 11 |
| Postoperative pain | D010149 | — | G89.18 | — | — | — | 3 | 7 | 10 |
| Vomiting | D014839 | HP_0002013 | R11.1 | — | — | 1 | 3 | 6 | 10 |
| Nausea | D009325 | HP_0002018 | R11.0 | — | — | 1 | 3 | 5 | 9 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | — | — | 1 | 2 | 6 | 9 |
| Bradycardia | D001919 | HP_0001662 | R00.1 | — | 1 | — | 5 | 3 | 9 |
Show 76 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Degenerative myopia | D047728 | — | H44.2 | 2 | 3 | 4 | — | 5 | 12 |
| General anesthesia | D000768 | — | — | — | 2 | 2 | — | 3 | 7 |
| Emergence delirium | D000071257 | — | — | — | 1 | 1 | — | 3 | 4 |
| Delirium | D003693 | — | R41.0 | — | 1 | 1 | — | 2 | 3 |
| Lymphoma | D008223 | — | C85.9 | 2 | 1 | 1 | — | — | 3 |
| Uveitis | D014605 | HP_0000554 | H20.9 | — | — | 1 | — | 1 | 2 |
| Premedication | D011292 | — | — | — | 2 | 2 | — | — | 2 |
| Replacement arthroplasty hip | D019644 | — | — | — | — | 1 | — | 1 | 2 |
| Chest pain | D002637 | HP_0100749 | R07.9 | — | — | 1 | — | 1 | 2 |
| Anisometropia | D015858 | HP_0012803 | H52.31 | — | — | 1 | — | 1 | 2 |
Show 16 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 2 | — | — | 2 | 4 |
| Neoplasms | D009369 | — | C80 | 2 | 2 | — | — | — | 3 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 2 | 1 | — | — | — | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | 2 | — | — | — | 2 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | — | — | 1 | 2 |
| Colonic neoplasms | D003110 | — | C18 | 1 | 2 | — | — | — | 2 |
| Rhinitis | D012220 | EFO_0008521 | J31 | 1 | 1 | — | — | — | 2 |
| Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | 1 | 1 | — | — | — | 2 |
| Heart arrest | D006323 | EFO_0009492 | I46 | — | 1 | — | — | 1 | 2 |
| Sarcoma | D012509 | — | — | — | 1 | — | — | — | 1 |
Show 22 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | 2 | 3 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | 1 | — | — | — | 1 | 2 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | 1 | — | — | — | 1 | 2 |
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | 2 | — | — | — | — | 2 |
| Sialorrhea | D012798 | HP_0002307 | K11.7 | 1 | — | — | — | 1 | 2 |
| Orthostatic intolerance | D054971 | — | — | 1 | — | — | — | 1 | 2 |
| Death | D003643 | PATO_0001422 | — | 1 | — | — | — | 1 | 2 |
| Digestive system physiological phenomena | D004068 | — | — | 1 | — | — | — | — | 1 |
| Gastrointestinal motility | D005769 | — | — | 1 | — | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
Show 16 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | — | — | 4 | 4 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | — | 3 | 3 |
| Analgesia | D000698 | — | — | — | — | — | — | 3 | 3 |
| Glaucoma | D005901 | EFO_0000516 | H40 | — | — | — | — | 2 | 2 |
| Conduction anesthesia | D000765 | — | — | — | — | — | — | 2 | 2 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | — | 2 | 2 |
| Psychomotor agitation | D011595 | — | — | — | — | — | — | 2 | 2 |
| Hernia | D006547 | HP_0100790 | K40-K46 | — | — | — | — | 2 | 2 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | — | 2 | 2 |
| Intravenous anesthesia | D000771 | — | — | — | — | — | — | 2 | 2 |
Show 80 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Atropine |
| INN | edrophonium chloride |
| Description | Atropine is a racemate composed of equimolar concentrations of (S)- and (R)-atropine. It is obtained from deadly nightshade (Atropa belladonna) and other plants of the family Solanaceae. It has a role as a muscarinic antagonist, an anaesthesia adjuvant, an anti-arrhythmia drug, a mydriatic agent, a parasympatholytic, a bronchodilator agent, a plant metabolite, an antidote to sarin poisoning and a oneirogen. It contains a (S)-atropine and a (R)-atropine. |
| Classification | Small molecule |
| Drug class | atropine derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2 |
Identifiers
| PDB | — |
| CAS-ID | 51-55-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL517712 |
| ChEBI ID | 16684 |
| PubChem CID | 174174 |
| DrugBank | DB00572 |
| UNII ID | QO611KSM5P (ChemIDplus, GSRS) |
Target
Agency Approved
CHRM3
CHRM3
CHRM2
CHRM2
CHRM1
CHRM1
CHRM5
CHRM5
CHRM4
CHRM4
Alternate
ADRA2A
ADRA2A
Organism
Homo sapiens
Gene name
ADRA2A
Gene synonyms
ADRA2R, ADRAR
NCBI Gene ID
Protein name
alpha-2A adrenergic receptor
Protein synonyms
adrenergic, alpha-2A-, receptor, Alpha-2 adrenergic receptor subtype C10, alpha-2-adrenergic receptor, platelet type, Alpha-2A adrenoceptor, Alpha-2A adrenoreceptor, Alpha-2AAR, alpha-2AAR subtype C10
Uniprot ID
Mouse ortholog
Adra2a (11551)
alpha-2A adrenergic receptor (Q3URE6)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Atropine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Atropine
+
Difenoxin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Atropine
+
Diphenoxylate
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 62,284 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,500 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use